New data indicates nearly 90% of patients experiencing anaphylaxis symptoms were successfully treated with a single dose of neffy nasal spray.
RT’s Three Key Takeaways:
- Real-World Effectiveness: Nearly 90% of patients experiencing anaphylaxis symptoms were successfully treated with a single dose of neffy nasal spray.
- Clinical Consistency: The treatment success rate for the nasal spray is nearly identical to the historical performance of epinephrine intramuscular injections.
- Large-Scale Analysis: These results represent the first large-scale report of treatment outcomes for neffy during routine clinical practice, according to data accepted for publication in the Annals of Allergy, Asthma and Immunology.
ARS Pharmaceuticals shared real-world evidence evaluating the clinical performance of neffy (epinephrine nasal spray) in patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy, according to a news release.
The findings represent the first large-scale analysis of treatment outcomes with neffy during routine clinical practice. The data was accepted for publication as a correspondence in the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology.
According to the report, 89.2% of 545 patients experiencing anaphylaxis symptoms were successfully treated with a single dose of neffy administered by a healthcare provider. Meta-analyses of food-induced anaphylaxis report a similar success rate of 88.9% for patients treated with a single dose of an epinephrine intramuscular injection or auto-injector.
“These data reinforce existing findings and is the first large-scale report of real-world treatment outcomes with neffy during anaphylaxis events. The finding that about 9 out of every 10 patients were successfully treated with a single dose of neffy in more than 500 patients is essentially identical to the historic response rates observed with epinephrine injection,” said Dr Thomas B Casale, professor of medicine and pediatrics and chief of clinical and translational research in the USF Health Morsani College of Medicine’s division of allergy and immunology at the University of South Florida, in a news release.
Casale added that the outcomes support the clinical interchangeability of neffy and epinephrine injection, noting that studies conducted for Food and Drug Administration (FDA) approval showed the nasal spray achieved blood levels and pharmacodynamic responses within the range of approved injectable products.
The data was collected through the neffy experience program, a retrospective observational analysis. In this program, healthcare providers were provided six doses of neffy to rescue patients experiencing anaphylaxis symptoms. As of the March 2025 data cut-off, 301 healthcare providers had responded to the survey, with 486 of 545 total patients successfully treated with a single 2 mg dose.
The FDA indicated neffy for the emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients weighing at least 33 lbs. While epinephrine auto-injectors are highly effective, the news release noted several limitations that lead to treatment delays, including fear of needles, lack of portability, and device complexity.
Current data suggests that while 20 million people in the US have been diagnosed with severe type I allergic reactions, only 3.2 million filled an epinephrine auto-injector prescription in 2023. Of those who fill prescriptions, only half consistently carry the device, and more than half either delay or do not administer the injection during an emergency, according to the news release.
